Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study

Lin, Liwu; Yan, Lei; Liu, Yuling; Yuan, Fang; Li, Hui; Ni, Jian

doi:10.1186/s13045-019-0783-9

Cited by 140 publications

(109 citation statements)

References 46 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…The apparent improvement in the survival of CML patients mainly occurred in high-income countries like the United States, France, and Japan [ 9 – 11 ]. The disease burden of CML distinctly varies in different countries due to diverse opportunities for early-stage screening, novel drugs and medical resources [ 12 , 13 ]. The worldwide disease burden of CML is worth evaluating, which can help us better understand the specific impact of this disease on public health.…”

Section: Introductionmentioning

confidence: 99%

“…The Global Burden of Disease (GBD) study 2017 contains epidemiologic data about 354 diseases across 195 countries and territories, providing an opportunity to understand the worldwide trends in the disease burden of CML [ 13 ]. Accordingly, we described the incidence, deaths, disability-adjusted life-years (DALYs), and its attributable risk factors of CML by age, sex, geographical regions, social-development index (SDI) on specific CML data from the (GBD) study 2017.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study

Ning

et al. 2020

Exp Hematol Oncol

View full text Add to dashboard Cite

Background Outcomes of chronic myeloid leukemia (CML) has been improved dramatically in the past two decades, but survival levels of CML patients varied in regions. Comprehensive epidemiological research is necessary to evaluate the global burden of CML. Methods All data used in our study came from the Global Burden of Disease (GBD) study 2017. Incidence cases, death cases, disability-adjusted life-years (DALYs), and its corresponding age-standardized rate between 1990 to 2017 were used to describe the distribution of CML burden, according to age, sex, social-demographic index (SDI), and countries. Data about attributable risk factors contributing to CML deaths and DALYs were also extracted and analyzed. Results Globally, the disease burden of CML gradually decreased from 1990 to 2017. Higher SDI countries achieved a remarkable effect on diminishing the CML burden. Conversely, due to population growth, the incidence cases, death cases, and DALYs of CML in lower SDI quintiles showed an upward trend. India had the most incidence cases and death cases of CML in the world. Additionally, smoking was the most significant attributable risk factor contributing to CML deaths and DALYs, followed by high body mass index. Conclusion The disease burden of CML decreased globally, especially in higher SDI countries in the past 28 years. The increasing incidence cases and death cases were mainly observed in lower SDI countries. Additionally, strategies to control modifiable risk factors such as smoking and high body mass index might be useful in diminishing mortality and DALYs.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study

Ning

et al. 2020

Exp Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…The global burden of cancer is rapidly increasing, and established risk factors for cancer include smoking, poor diet, overweight, and physical inactivity. 1,2 The burden of cancers is expected to be further increased by increases in these risk factors, particularly in less developed countries. 3,4 TheGBD study reported that the global burden of childhood cancers mainly existed in developing countries in 2017, 5 and there are age and gender differences in the global trends of incidence and death for specific cancers.…”

Section: Introductionmentioning

confidence: 99%

<p>Secular Trend of Cancer Death and Incidence in 29 Cancer Groups in China, 1990–2017: A Joinpoint and Age–Period–Cohort Analysis</p>

Liu¹,

Zhou²,

Wang³

et al. 2020

CMAR

View full text Add to dashboard Cite

Purpose: China has a heavy cancer burden. We aimed to quantitatively estimate the secular trend of cancer mortality and incidence in China. Methods: We extracted numbers, age-specific and age-standardized rates of 29 cancer groups (from 1990 to 2017) from the Global Burden of Disease (GBD) study in 2017. We estimated rates of major cancer types for annual percent change by Joinpoint regression, and for age, period, and cohort effect by an age-period-cohort model. Results: In 2017, breast cancer had the highest incidence rate in females. Lung cancer had the highest mortality and incidence rates in males. Although the age-standardized incidence rate of prostate cancer ranked second highest in males, it increased by 112% from 1990 to 2017. Individuals aged over 50 years were at high risk of developing cancer, and the number of deaths at this age accounted for over 89% of all cancers in all age groups. When compared with the global average level, the age-standardized mortality and incidence rates of both liver and esophageal cancers were 2.1 times higher in China, and stomach, lung and nasopharyngeal cancers in China also had high levels (more than 1.5 times higher). During 1990-2017, most of the 29 cancers exhibited an increasing incidence trend, and Joinpoint regression demonstrated increasing mortality of some major cancers. The period effect indicated that the risk of mortality and incidence due to the main cancers generally increased during 1992-2017. Conclusion: Trend analysis provided information on the effects of prevention strategies and targeted interventions on the occurrence of different cancers. Etiological studies need to be conducted on some major cancers in the Chinese population.

show abstract

“…In our previous papers we reported the original rearrangement of spiro-fused pyrimidines and 1,3-benzoxazines into acridines and benzoxanthenes, respectively [48][49][50][51]. We found that treatment of spiro thienopyrimidine 3a with an excess of Vilsmeier-Haack reagent for 4 days at room temperature afforded 1-cyclohex-1-en-1-yl-5,6,7,8-tetrahydro [1]benzothieno[2,3-d]pyrimidin-4(1H)one 10 in a moderate yield. The same rear-rangement product was isolated when the reagents were heated at 100-110ºС for 3 h (Scheme 3).…”

Section: Resultsmentioning

confidence: 98%

“…Over the past few decades, the survival of cancer patients has improved significantly due to the progress in early detection and treatment [1].…”

Section: Introductionmentioning

confidence: 99%

Spirocyclic thienopyrimidines: synthesis, new rearrangements under Vilsmeier conditions and in silico prediction of anticancer activity

et al. 2020

View full text Add to dashboard Cite

Aim. To find novel anticancer lead molecules among easily available spiro-fused thieno[2,3-d] pyrimidines. Methods. Organic synthesis, spectral methods and molecular docking. Results. New spiro heterocycles were synthesized by condensation of 2-aminothiophene-3-carbonitriles with cyclic ketones via Gevald reaction. Other model spirocyclic compounds were prepared by the reaction of 3-aminothieno[2,3-b]pyridine-2-carboxamides with cyclohexanone under acidic conditions. According to the docking studies against the EGFR WT the synthesized compounds revealed good binding energies ranging from-8.4 to-10.2 kcal/mol. The compounds were tested as inhibitors of protein kinase CK; 7',8',9',10'-tetrahydro-1'H-spiro[cyclohexane-1,2'-pyrimido[4',5':4,5]thieno[2,3-b]quinolin]-4'(3'H)-one showed the best binding energy while be bound by a hydrogen bond to Val66 amino acid residue. This compound also showed good results as a potential inhibitor of B-Raf kinase. Conclusion. New spiro-fused thieno[2,3d]pyrimidines have been synthesized. The inhibition activity of novel compounds as potential inhibitors of the EGFR, CK2, FGFR1 and B-raf kinases was examined. We found that spirofused thieno[2,3-d]pyrimidines undergo the rearrangement under Vilsmeier-Haack conditions to afford hitherto undescribed thienopyrimidines and-quinolines. The docking studies revealed that the rearranged products do not tend to form hydrogen bonds with the kinase amino acid residues and show moderate binding energies. Therefore, in contrast to the spiro-fused thieno[2,3-d]pyrimidines, the rearranged products cannot be considered as perspective targets for further screening.

show abstract

Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study

Cited by 140 publications

References 46 publications

Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study

Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study

<p>Secular Trend of Cancer Death and Incidence in 29 Cancer Groups in China, 1990–2017: A Joinpoint and Age–Period–Cohort Analysis</p>

Spirocyclic thienopyrimidines: synthesis, new rearrangements under Vilsmeier conditions and in silico prediction of anticancer activity

Contact Info

Product

Resources

About